Pfizer (PFE)
(Delayed Data from NYSE)
$25.40 USD
+0.14 (0.55%)
Updated Apr 26, 2024 04:01 PM ET
After-Market: $25.44 +0.04 (0.16%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Price, Consensus and EPS Surprise
PFE 25.40 +0.14(0.55%)
Will PFE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PFE
Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
Other News for PFE
7 Dividend Stocks to Buy Now for Steady Returns in Any Market
Pfizer gets FDA approval for hemophilia B gene therapy Beqvez
Pfizer gets FDA approval for hemophilia B gene therapy Beqvez
Pfizer (NYSE:PFE) Notches Up on New FDA Approval
US approves Pfizer gene therapy treatment for haemophilia